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	 A	 simple,	 precise,	 rapid,	 and	 low‐cost	 conductometric	 method	 for	 determination	 of
naftidrofuryl	 oxalate,	 propafenone	HCl	 and	 sotalol	 HCl	 in	 pure	 form	 and	 in	 pharmaceutical
formulations	using	silver	nitrate	has	been	described.	The	method	is	based	on	the	precipitation
of	oxalate	or	chloride	ions	coming	from	the	cited	drugs	with	silver	ions,	yielding	silver	oxalate
or	silver	chloride	and	the	conductance	of	the	solution	is	measured	as	a	function	of	the	volume
of	titrant.	The	studied	drugs	were	evaluated	in	double	distilled	water	in	the	range	of	1‐15	mg.
Various	 experimental	 conditions	 were	 established	 and	 results	 obtained	 showed	 good
recoveries	 with	 relative	 standard	 deviation	 of	 0.909,	 0.955	 and	 0.983	 for	 naftidrofuryl,
propafenone	and	sotalol,	respectively.	The	proposed	procedures	were	applied	successfully	to
the	 analysis	 of	 these	 drugs	 in	 their	 pharmaceutical	 formulations.	 Results	 were	 favorably
comparable	to	the	official	or	reference	methods.	
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1.	Introduction	
	
Naftidrofuryl	 oxalate	 is	 known	 as	 nafronyl	 oxalate,	 (2‐
(diethylaminoethyl)‐2‐[(naphthalene‐1‐yl)methyl]‐3‐(tetra‐
hydrofuran‐2‐yl)propanoate	hydrogen	oxalate)	[1].	It	is	used	as	
a	 vasodilator	 in	 the	 treatment	 of	 peripheral	 and	 cerebral	
vascular	 disorders.	 It	 is	 claimed	 to	 enhance	 cellular	 oxidative	
capacity	 thereby	 protecting	 cells	 against	 the	 results	 of	
ischaemia	[2].		
Few	 analytical	 methods	 were	 reported	 for	 the	
determination	 of	 naftidrofuryl	 in	 biological	 fluids	 and/or	
pharmaceutical	preparations.	Most	of	these	studies	focused	on	
kinetic	 spectrophotometry	 [3],	 derivative	 spectrophotometry,	
spectrofluorimetry,	 differential‐pulse	 voltammetry	 [4],	 HPLC‐
fluorimetric	 [5,6],	 HPLC‐UV	 detection	 methods	 [7,	 8]	 and	
phosphorimetric	 analysis	 [9‐12].	 Others	 include	 a	 potentio‐
metric	method	with	nafronyl	 ion‐selective	electrodes	[13]	and	
flow	injection	analysis	with	fluorescence	optosensor	[14]. 
Propafenone	 hydrochloride	 is	 [2‐(2‐hydroxy‐3‐propyl‐
aminopropoxy)‐3‐phenylpropio	 phenone	 hydrochloride]	 [15].	
It	 is	 used	 in	 the	 treatment	 of	 cardiac	 arrhythmias	 [2].	 A	
spectrophotometric	 [16]	 and	 spectrofluorimetric	 methods	
were	 reported	 for	 its	 determination	 [17].	 Several	 methods	
including	capillary	electrophoresis	[18,19],	HPLC	methods	[20‐
23]	 were	 reported	 for	 propafenone	 enantio	 selective	
determination	 and	 its	 metabolites	 in	 human	 plasma.	 Other	
reported	methods	of	analysis	include	LC‐MS	[24].	
Sotalol	 hydrochloride	 is	 N‐[4‐[(1RS)‐1‐hydroxy‐2‐[(1‐
methylethyl)amino]ethyl]phenyl]methanesulphonamide	
hydrochloride	[1].	It	is	a	non‐cardio	selective	beta	blocker	with	
class	 II	and	 III	antiarrhythmic	properties	 [2].	Several	methods	
were	 used	 for	 sotalol	 HCl	 determination	 in	 pure	 and	
pharmaceutical	 dosage	 forms.	 These	 methods	 include	
spectrophotometric	[25‐29],	spectrofluorimetric	[30,31],	HPLC	
[29,32],	 	LC	[33],	capillary	zone	electrophoresis	[34]	and	NMR	
spectroscopic	methods	[35].	
Silver	 nitrate	 has	 been	 used	 for	 conductometric	
determination	 of	 many	 drugs	 such	 as	 ciprofloxacin	 HCl	 [36],	
metformin	 hydrochloride	 [37]	 and	 verapamil	 hydrochloride	
[38].	 In	 this	 study,	 a	 simple,	 precise,	 rapid,	 and	 low‐cost	
conductometric	 titration	 method	 for	 the	 determination	 of	
naftidrofuryl	 oxalate,	 propafenone	 HCl	 and	 sotalol	 HCl	 in	
pharmaceuticals	is	proposed	using	silver	nitrate	as	titrant.	
	
2.	Experimental	
	
2.1.	Instrumentation	
	
The	 Jenway	 470	 model	 portable	 conductivity/TDS	 meter	
was	used	for	the	measurement	of	conductance.	
	
2.2.	Materials	and	reagents	
	
Naftidrofuryl	oxalate	was	obtained	from	Mina	Pharm,	Cairo,	
Egypt	 under	 license	 of	 Merck	 Santé	 France,	 Propafenone	 HCl	
was	purchased	 from	Kahira	Pharm.	and	Chem.	 Ind.	Co.,	under	
license	 of	 Abott	 Laboratories.	 Sotalol	 HCl	 was	 obtained	 from	
Amoun	Pharm,	Egypt.	5	x	10‐3	M	silver	nitrate	was	used.	
	
2.3.	Standard	drug	solutions 
	
Aqueous	 solution	 of	 1	 mg/mL	 naftidrofuryl	 oxalate,	
propafenone	HCl	and	sotalol	HCl	were	prepared	by	dissolving	
100	mg	of	the	pure	drug	in	100	mL	bi‐distilled	water.		
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Scheme	1	
	
	
2.4.	Pharmaceutical	preparations	
	
1. Praxilene®	 tablets	 (Mina	 Pharm,	 under	 licence	 of	
Merck	 Santé	 France,	 Egypt)	 labeled	 to	 contain	 200	 mg	
naftidrofuryl	oxalate	per	tablet.		
2. Rytmonorm®	tablets	(Kahira	Pharm.	and	Chem.	Ind.	
Co.,	under	 the	 licence	 from	Abott	Laboratories,	Egypt)	 labeled	
to	contain	150	mg	Propafenone	HCl	per	tablet.	
3. Betacor	 tablets	 (Amoun	 Pharm,	 Egypt)	 labeled	 to	
contain	80	mg	sotalol	per	tablet.	
	
2.5.	General	procedure	
	
Aliquots	of	drug	 solution	 (1‐15	mg)	were	 transferred	 to	 a	
50	mL	 calibrated	 flasks,	 volumes	 were	made	 up	 to	 the	 mark	
using	 bi‐distilled	 water.	 The	 contents	 of	 the	 calibrated	 flask	
were	 transferred	 to	 a	 beaker,	 the	 conductivity	 cell	 was	
immersed	and	5	x	10‐3	M	silver	nitrate	was	used	 for	 titration.	
The	conductance	was	measured	subsequent	to	each	addition	of	
reagent	 solution	 and	 after	 thorough	 stirring	 for	 two	min.,	 the	
conductance	was	 corrected	 for	 dilution	 [39]	 by	means	 of	 the	
equation	(1),	assuming	that	conductivity	is	a	linear	function	of	
dilution.	
	
Ω‐1correct	=	Ω‐1obs	[v1+v2/v1]	 	 	 	 (1)	
	
where	Ω‐1correct	is	the	corrected	electrolytic	conductivity,	Ω‐1obs	
is	the	observed	electrolytic	conductivity,	v1	is	the	initial	volume	
and	v2	is	the	volume	of	reagent	added. 
A	 graph	 of	 corrected	 conductivity	 versus	 the	 volume	 of	
added	 titrant	was	 constructed	 and	 end‐point	was	 determined	
conductometrically.		
The	amount	of	drugs	under	study	was	calculated	according	
to	the	equation	(2),	
	
Amount	of	drug	=	V.M.R	/	N	 	 	 	 (2)	
	
where	V	is	volume	of	titrant,	M	is	molecular	weight	of	drug,	R	is	
molar	 concentration	 of	 titrant	 and	N	 is	 no	 of	moles	 of	 titrant	
consumed	by	one	mole	of	drug.	
	
	
2.6.	Assay	of	the	pharmaceutical	formulations	
	
Ten	 tablets	were	 powdered	 and	 an	 amount	 equivalent	 to	
100	mg	naftidrofuryl	oxalate,	propafenone	HCl	and	sotalol	HCl	
was	 shaken	 with	 10	 mL	 distilled	 water,	 then	 filtered	 and	
diluted	to	100	mL	with	distilled	water.	
	
3.	Results	and	discussion 
	
3.1.	Method	development	
	
Conductometric	methods	of	analysis	are	well	suited	for	the	
determination	 of	 endpoints	 in	 precipitation	 titrations,	 where	
the	shape	of	the	titration	curves	can	be	predicted	by	summing	
the	ionic	conductance	of	the	various	species	during	the	course	
of	 titration.	 On	 using	 silver	 nitrate	 as	 a	 titrant	 for	 the	
determination	 of	 naftidrofuryl	 oxalate,	 propafenone	 HCl	 and	
sotalol	 HCl,	 silver	 oxalate	 or	 silver	 chloride	 is	 precipitated	
(Scheme	1)	leading	to	a	straight	line	during	the	first	segment	of	
the	 titration	 curve.	 The	 second	 segment	 of	 this	 curve	
corresponds	to	the	excess	of	AgNO3,	Figures	1‐3.		
	
 
Figure	1.	Conductometric	titration	curve	of	5	mg	naftidrofuryl	oxalate vs	
silver	nitrate	(5×10‐3	M).	
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Table	1.	Conductometric	determination	of	naftidrofuryl	oxalate,	propafenone	HCl	and	sotalol	HCl	using	silver	nitrate*.	
Compound	 Naftidrofuryl	oxalate	 Propafenone	HCl Sotalol	HCl	
Parameters	
Taken		
(mg)	
Found		
(mg)	
Recovery	
(%)	
Taken		
(mg)	
Found	
(mg)	
Recovery	
(%)	
Taken	
(mg)	
Found	
(mg)	 Recovery	(%)
	
1.000	 0.995	 99.46	 1.000 0.997 99.68 1.000 1.002	 100.19
3.000	 3.055	 101.82	 3.000 3.041 101.37 3.000 2.975	 99.18
5.000	 5.044	 100.88	 5.000	 4.984	 99.68	 5.000	 4.964	 99.28	
7.000	 6.962	 99.46	 7.000 7.096 101.37 7.000 6.983	 99.75
10.000	 10.064	 100.64	 10.000	 10.053	 100.26	 10.000	 10.171	 101.71	
15.000 15.037	 100.25	 15.000 14.868 99.12 15.000 14.876	 99.18
MeanS.D.	 99.850.907	 99.400.949	 99.680.980	
N	 6	 6 6
V 0.823	 0.901 0.960
S.D.	 0.907	 0.949 0.980
R.S.D.	 0.909	 0.955 0.983
S.E.	 0.371	 0.388	 0.400	
*	 S.D.:	 	 Standard	 deviation;	 N:	 number	 of	 experiments;	 V:	 Variance;	 R.S.D.:	 Relative	 standard	 deviation;	 S.E.:	 Standard	 error;	Mean:	Mean	 of	 three	 different	
experiments.	
	
	
 
	
Figure	2.	Conductometric	titration	curve	of	5	mg	propafenone	HCl	vs	silver	
nitrate	(5×10‐3	M).	
	
	
 
	
Figure	3.	Conductometric	titration	curve	of	5	mg	sotalol	HCl	vs silver	nitrate	
(5×10‐3	M).	
	
Investigations	 were	 carried	 out	 to	 establish	 the	 most	
favorable	 conditions	 for	 the	 reaction	 attain	 end	 point.	 The	
influence	 of	 some	 variables	 on	 the	 reaction	 has	 been	 tested.	
The	 optimum	 conditions	 for	 performing	 the	 titration	 in	 a	
quantitative	manner	were	elucidated	as	described	below.		
	
3.1.1.	Titrations	in	different	media	were	attempted	to	obtain	
the	best	results	
	
Preliminary	 experiments	 were	 tried	 for	 each	 drug	 in	 (i)	
Aqueous	 solutions	 of	 both	 drug	 and	 reagent,	 (ii)	 Ethanolic	
solutions	 of	 both	 drug	 and	 reagent,	 (iii)	 Drug	 and	 reagent	
solutions	in	ethanol‐water	(50%,	v/v)	mixture,	(iv)	Methanolic	
solutions	 of	 both	 drug	 and	 reagent,	 (v)	 Drug	 and	 reagent	
solutions	 in	methanol‐water	 (50%	 v/v)	mixture,	 (vi)	 Acetone	
solutions	of	both	drug	and	reagent	and	(vii)	Drug	and	reagent	
solution	in	acetone‐water	(50%	v/v)	mixture.		
It	was	found	that	procedure	in	aqueous	media	was	the	most	
suitable	 for	successful	results,	as	 in	case	of	 (vi),	(vii),	 (ii),	 (iii),	
the	 initial	 conductance	 was	 very	 low,	 the	 increase	 in	
conductance	after	silver	nitrate	addition,	also	was	very	 low	or	
absent	and	there	was	no	end	point	inflection,	and	so	end	point	
detection	is	very	difficult.		
In	 case	 of	 (i),	 (iv),	 (v),	 the	 same	 initial	 conductance	 was	
obtained,	 then	 the	 conductance	 increased	 after	 silver	 nitrate	
addition,	 however	 in	 water	 medium	 sharpest	 end	 point	 was	
detected	 So	water	was	 the	 best	 and	 cheapest	 choice	medium	
for	conductometric	titration.	
	
3.1.2.	Reagent’s	concentration	
	
The	 optimum	 concentrations	 of	 silver	 nitrate	 and	
ammonium	 reineckate	were	 5	 x	 10‐3	M	 to	 achieve	 a	 constant	
and	 highly	 stable	 conductance	 reading	 after	 2.0	 min	 mixing.	
Concentrations	 less	 than	 these	 lead	 to	 unstable	 readings	 and	
more	time	was	needed	to	obtain	constant	conductance	values.	
		
3.1.3.	Effect	of	temperature	
	
Different	 temperatures	were	tested	(25,	30,	35	and	40	 oC)	
and	it	was	found	that	the	same	results	were	obtained	so	room	
temperature	 (25	 oC)	 was	 selected	 for	 determination.	
Temperature	 couldn't	 be	 increased	 more	 than	 40	 oC	 as	
conductometry	 electrode	 (conductivity	 cell)	 could	 be	 affected	
by	elevated	temperature.		
	
3.2.	Validation	of	the	studied	method	
	
In	 order	 to	 address	 the	 validity	 of	 the	proposed	methods,	
statistical	 analysis	 of	 the	data	 obtained	 from	 their	 application	
on	 the	 drugs	 in	 the	 pure	 form	 and	 in	 pharmaceutical	
formulations	was	performed.	
	
Recovery	%	=	(Found	concentration	/	Taken	concentration)	×	100	 (3)	
	
For	application	(standard	addition	technique),		
	
End	point	of	authentic	=	End	point	of	(authentic	+	End	point	of	tablets)	‐	End	
point	of	tablets	 	 	 	 	 (4)	
	
Results	revealed	in	(Tables	1,	2)	showed	that	the	proposed	
methods	 are	 satisfactorily	 accurate,	 precise	 and	 reproducible	
over	a	concentration	range	of	1‐15	mg	for	all	the	studied	drugs	
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Table	2.	Conductometric	determination	of	naftidrofuryl	oxalate	propafenone	HCl	and	sotalol	HCl	in	their	pharmaceutical	preparations	using	silver	nitrate	*.		
Compound	 Naftidrofuryl	oxalate		
(Praxilene	tablets	)	
Propafenone	HCl		
(Rytmonorm	tablets)
Sotalol	HCl		
(Betacor	tablets)	
Parameters	 Taken	 Added Found	 Recovery		 Taken Added Found Recovery Taken Added Found	 Recovery
(mg/mL)	 (%)	 (mg/mL)	 (%)	 (mg/mL)	 (%)	
1.000	 0.000	 1.006	 100.64	 1.000 0.000 1.014 101.37 1.000 0.000	 0.987	 98.67
1.000	 2.000	 1.977	 98.86	 1.000 2.000 1.977 98.84 1.000 2.000	 2.019	 100.95
1.000	 4.000	 3.966	 99.16 1.000	 4.000	 4.055	 101.37	 1.000	 4.000	 4.023	 100.57	
1.000	 6.000	 5.956	 99.26	 1.000 6.000 5.964 99.40 1.000 6.000	 6.057	 100.95
1.000	 9.000	 8.939	 99.32	 1.000	 9.000	 9.039	 100.43	 1.000	 9.000	 9.032	 100.36	
1.000	 14.000 14.150	 101.06	 1.000 14.000 14.020 100.16 1.000 14.000 13.890	 99.12
Mean±S.D.	 99.53	±0.873	 100.04	±	0.974 100.41	±	0.714	
N	 5	 5 5
V	 0.761	 0.950 0.510
S.D.	 0.873	 0.974 0.8714
S.E.	 0.390	 0.436 0.319
*	 S.D.:	 	 Standard	 deviation;	 N:	 number	 of	 experiments;	 V:	 Variance;	 R.S.D.:	 Relative	 standard	 deviation;	 S.E.:	 Standard	 error;	Mean:	Mean	 of	 three	 different	
experiments.	
	
	
Table	3.	Statistical	data	for	the	conductometric	determination	of	naftidrofuryl	oxalate,	propafenone	HCl	and	sotalol	HCl	using	silver	nitrate.		
Drug	 Parameters	 Silver	nitrate	method	 Reference	or	reported	method	
Naftidrofuryl	oxalate 
MeanS.D	 99.850.907 100.050.420	[1]	
N	 6 3
Variance	 0.823 0.175	
Student‐t‐test	 0.352	(2.365)*	 ‐	
F‐test	 4.703	(5.790)* ‐
Propafenone	HCl 
MeanS.D	 99.400.949	 100.290.630	[16]	
N	 6 3
Variance	 0.901 0.395	
Student‐t‐test	 1.447	(2.365)*	 ‐	
F‐test	 2.281	(5.790)*	 ‐	
Sotalol	HCl 
MeanS.D	 99.690.980 100.110.930	[31]	
N	 6 8
Variance	 0.960 0.865	
Student‐t‐test	 0.818	(2.179)* ‐
F‐test	 1.110	(3.970)*	 ‐	
*	Theoretical	values	of	t	and	F	at	p	=	0.05.	
	
	
Student's	 t‐test	 and	F‐test	 (at	95%	confidence	 level)	were	
applied	 to	 the	 results	 obtained	 compared	 with	 that	 obtained	
when	applying	the	official	[1,	15]	or	reported	[27]	methods	for	
naftidrofuryl	 oxalate,	 propafenone	 HCl	 or	 sotalol	 HCl,	
respectively.	 The	 results	 showed	 that	 there	 is	 no	 significant	
difference	 between	 the	 proposed	 and	 official	 or	 reported	
methods.	The	 results	of	different	 statistical	data	 are	 shown	 in	
Table	3.	
	
4.	Conclusions	
	
The	simple	and	rapid	procedure	described	in	this	paper	can	
be	an	alternative	to	the	more	complex	and	expensive	methods	
for	assay	of	naftidrofuryl	oxalate,	propafenone	HCl	and	sotalol	
HCl.	There	is	no	interference	from	the	common	excipients.	The	
proposed	method	 is	 easy,	 cheap,	 accurate	 and	 very	 useful	 for	
the	determination	of	the	studied	drugs	in	their	pharmaceutical	
formulations	 and	 can	 be	 applied	 in	 laboratories	 for	 routine	
analysis.	
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